IL6 and laryngotracheoesophageal cleft: Evidence has shown that the combined treatment of metformin plus TKI-gefitinib promotes EMT-phenotype regression in TKI-resistant LC cells, increasing E-cadherin protein levels and blocking Interleukin-6 (IL-6) signaling [21].